vs
La Rosa Holdings Corp.（LRHC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是La Rosa Holdings Corp.的1.5倍（$30.3M vs $20.2M），La Rosa Holdings Corp.净利率更高（-27.4% vs -221.3%，领先194.0%），REGENXBIO Inc.同比增速更快（43.0% vs 3.2%），过去两年La Rosa Holdings Corp.的营收复合增速更高（72.5% vs 39.4%）
拉罗萨控股旗下的万拉罗萨父子通心粉公司由西西里移民文森佐·拉罗萨于1914年创立，发展至今已成为美国规模领先的区域知名食品品牌，可生产四十余种意面产品，在当地市场拥有较高的认可度。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
LRHC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.5倍
$20.2M
营收增速更快
RGNX
高出39.8%
3.2%
净利率更高
LRHC
高出194.0%
-221.3%
两年增速更快
LRHC
近两年复合增速
39.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.2M | $30.3M |
| 净利润 | $-5.5M | $-67.1M |
| 毛利率 | 8.4% | — |
| 营业利润率 | -24.7% | -190.0% |
| 净利率 | -27.4% | -221.3% |
| 营收同比 | 3.2% | 43.0% |
| 净利润同比 | -125.7% | -31.2% |
| 每股收益（稀释后） | $-5.44 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LRHCRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $20.2M | $29.7M | ||
| Q2 25 | $23.2M | $21.4M | ||
| Q1 25 | $17.5M | $89.0M | ||
| Q4 24 | $17.7M | $21.2M | ||
| Q3 24 | $19.6M | $24.2M | ||
| Q2 24 | $19.1M | $22.3M | ||
| Q1 24 | $13.1M | $15.6M |
净利润LRHCRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-5.5M | $-61.9M | ||
| Q2 25 | $78.4M | $-70.9M | ||
| Q1 25 | $-95.7M | $6.1M | ||
| Q4 24 | $-5.1M | $-51.2M | ||
| Q3 24 | $-2.5M | $-59.6M | ||
| Q2 24 | $-2.3M | $-53.0M | ||
| Q1 24 | $-4.6M | $-63.3M |
毛利率LRHCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 8.9% | 70.2% | ||
| Q3 24 | 8.3% | 48.8% | ||
| Q2 24 | 8.3% | 52.5% | ||
| Q1 24 | 8.9% | 72.6% |
营业利润率LRHCRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | -24.7% | -176.3% | ||
| Q2 25 | -10.6% | -296.3% | ||
| Q1 25 | -26.7% | 13.6% | ||
| Q4 24 | -17.1% | -242.1% | ||
| Q3 24 | -8.9% | -256.6% | ||
| Q2 24 | -9.7% | -251.3% | ||
| Q1 24 | -35.0% | -408.8% |
净利率LRHCRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -27.4% | -208.3% | ||
| Q2 25 | 337.8% | -331.8% | ||
| Q1 25 | -546.5% | 6.8% | ||
| Q4 24 | -28.7% | -241.3% | ||
| Q3 24 | -12.5% | -246.3% | ||
| Q2 24 | -12.2% | -237.7% | ||
| Q1 24 | -35.1% | -405.4% |
每股收益（稀释后）LRHCRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $-5.44 | $-1.20 | ||
| Q2 25 | $15.25 | $-1.38 | ||
| Q1 25 | $-5.86 | $0.12 | ||
| Q4 24 | $28.54 | $-0.99 | ||
| Q3 24 | $-16.49 | $-1.17 | ||
| Q2 24 | $-12.49 | $-1.05 | ||
| Q1 24 | $-0.35 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.0M | $230.1M |
| 总债务越低越好 | $642.8K | — |
| 股东权益账面价值 | $1.6M | $102.7M |
| 总资产 | $21.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.41× | — |
8季度趋势，按日历期对齐
现金及短期投资LRHCRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $4.0M | $274.2M | ||
| Q2 25 | $5.1M | $323.3M | ||
| Q1 25 | $2.9M | $267.9M | ||
| Q4 24 | $1.4M | $234.7M | ||
| Q3 24 | $1.8M | $255.5M | ||
| Q2 24 | $1.6M | $290.4M | ||
| Q1 24 | $1.1M | $338.7M |
总债务LRHCRGNX
| Q4 25 | — | — | ||
| Q3 25 | $642.8K | — | ||
| Q2 25 | $644.3K | — | ||
| Q1 25 | $645.9K | — | ||
| Q4 24 | $647.6K | — | ||
| Q3 24 | $649.2K | — | ||
| Q2 24 | $650.8K | — | ||
| Q1 24 | $652.4K | — |
股东权益LRHCRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $1.6M | $161.5M | ||
| Q2 25 | $3.4M | $213.7M | ||
| Q1 25 | $-87.5M | $274.2M | ||
| Q4 24 | $2.6M | $259.7M | ||
| Q3 24 | $5.0M | $301.4M | ||
| Q2 24 | $4.7M | $348.3M | ||
| Q1 24 | $5.6M | $390.7M |
总资产LRHCRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $21.7M | $525.2M | ||
| Q2 25 | $22.9M | $581.0M | ||
| Q1 25 | $21.0M | $490.9M | ||
| Q4 24 | $19.4M | $466.0M | ||
| Q3 24 | $19.7M | $519.1M | ||
| Q2 24 | $18.7M | $569.4M | ||
| Q1 24 | $16.3M | $629.2M |
负债/权益比LRHCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.12× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流LRHCRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $-1.3M | $-56.0M | ||
| Q2 25 | $-1.4M | $-49.3M | ||
| Q1 25 | $-3.5M | $33.6M | ||
| Q4 24 | $-1.1M | $-31.6M | ||
| Q3 24 | $-591.6K | $-40.5M | ||
| Q2 24 | $-803.1K | $-45.5M | ||
| Q1 24 | $-538.3K | $-55.5M |
自由现金流LRHCRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率LRHCRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度LRHCRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率LRHCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
